<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02063828</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00038743</org_study_id>
    <secondary_id>U10CA081851</secondary_id>
    <secondary_id>WF-01213</secondary_id>
    <secondary_id>1UG1CA189824</secondary_id>
    <secondary_id>2R25CA122061-07</secondary_id>
    <secondary_id>R21CA182111-01</secondary_id>
    <secondary_id>NCI-2014-02413</secondary_id>
    <nct_id>NCT02063828</nct_id>
  </id_info>
  <brief_title>Reducing Lung Cancer-Related Anxiety (RELAX)</brief_title>
  <acronym>RELAX</acronym>
  <official_title>Reducing Lung Cancer-Related Anxiety (RELAX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to compare the effects of music and different levels of&#xD;
      device-guided breathing on anxiety and shortness of breath in lung cancer survivors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES&#xD;
&#xD;
        1. To assess feasibility (accrual, participation, adherence, retention) of a randomized&#xD;
           study of device-guided breathing and music in 75 post-treatment lung cancer survivors&#xD;
           with significant anxiety.&#xD;
&#xD;
        2. To obtain preliminary data on the variability and efficacy of two doses of a&#xD;
           device-guided breathing intervention versus a music control group for reducing anxiety&#xD;
           (primary outcome) and for improving self-reported dyspnea and respiratory functioning&#xD;
           (secondary outcomes) in post-treatment lung cancer survivors.&#xD;
&#xD;
        3. To select the optimal dose of the device-guided breathing intervention (15 minutes&#xD;
           once/day or twice/day) for subsequent randomized study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Took too long to accrue participants, stopped for feasibility concerns&#xD;
  </why_stopped>
  <start_date type="Actual">July 30, 2015</start_date>
  <completion_date type="Actual">December 23, 2019</completion_date>
  <primary_completion_date type="Actual">December 23, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retention - Number of Participants Who Complete the Final Assessment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Retention will be calculated as the number of participants who complete the final assessment divided by number randomized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence- Amount of Time the Device is Used</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adherence will be calculated as the actual amount of time the device is used divided by the prescribed time. Successful adherence will be defined as use of the device ≥80% of the time assigned.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accrual Rate- Number of Patients Accrued to the Study</measure>
    <time_frame>Time from study opening to study close ~46.42 months</time_frame>
    <description>The accrual rate will be calculated as the number of patients accrued to the study divided by the number of months of accrual.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for Anxiety as Measured by Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To obtain preliminary data on the variability and efficacy of two doses of a device-guided breathing intervention versus a usual breathing control group for reducing anxiety. This is a 14-item self-report measure of cognitive and behavioral symptoms of anxiety and depression; clinically significant symptoms are indicated by a score of greater than or equal to 8 with a range from 0 to 42. Higher scores indicate more anxiety.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Salivary Cortisol Levels</measure>
    <time_frame>12 weeks</time_frame>
    <description>Cortisol levels will be assessed upon awakening, 30 minutes post-awakening, and at bedtime for three consecutive days at baseline and three consecutive days.</description>
  </other_outcome>
  <other_outcome>
    <measure>DNA Methylation Levels</measure>
    <time_frame>12 weeks</time_frame>
    <description>DNA methylation levels will be measured To determine if changes in anxiety are associated with methylation</description>
  </other_outcome>
  <other_outcome>
    <measure>Gene Expression Levels</measure>
    <time_frame>12 weeks</time_frame>
    <description>The DNA methylation and gene expression patterns between the different groups.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A - Device Guided Breathing Low Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B - Device guided breathing high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Group C - Usual Breathing Control Group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Group A - Device guided breathing low dose</intervention_name>
    <description>Group A: 15 minutes once a day, 5 days a week for 12 weeks.</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>RESPeRATE (InterCure Ltd) Device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Group B - Device guided breathing high dose</intervention_name>
    <description>Group B - 15 minutes twice a day, 5 days a week for 12 weeks.</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>RESPeRATE (InterCure Ltd) Device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Group C - Usual Breathing Control Group</intervention_name>
    <description>Group C - 15 minutes per day, 5 days a week for 12 weeks.</description>
    <arm_group_label>Group C</arm_group_label>
    <other_name>RESPeRATE (InterCure Ltd) Device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Past History of any lung cancer&#xD;
&#xD;
          -  For Stage I-III disease, patients should be 2-24 months post-completion of surgery,&#xD;
             radiation therapy and/or chemotherapy with no further planned treatment during the&#xD;
             12-week study and no evidence of disease.&#xD;
&#xD;
          -  For Stage IV disease, patients may be receiving no treatment or may be receiving&#xD;
             maintenance treatment with a target agent, chemotherapy, or immunotherapy provided the&#xD;
             most recent imaging does not demonstrate progressive disease.&#xD;
&#xD;
          -  After completion of all three screening questionnaires, participant must score&#xD;
             accordingly on at least one questionnaire to be eligible.&#xD;
&#xD;
          -  Willing/able to attend brief introductory session and use assigned device for the&#xD;
             assigned period of time (15 minutes once or twice per day), at least 5 days per week&#xD;
             for 12 weeks&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Must have telephone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient does not understand English&#xD;
&#xD;
          -  Active lung infection&#xD;
&#xD;
          -  Progressive cancer (must be considered no evidence of disease or stable)&#xD;
&#xD;
          -  Any change in psychotropic medications in past 30 days&#xD;
&#xD;
          -  Hearing loss that would preclude participating in interventions. Adequate hearing to&#xD;
             participate will be determined via: (1) Response of &quot;no&quot; to the question [&quot;Do you have&#xD;
             a hearing problem now?&quot;] Participants with hearing aids will be allowed to enroll as&#xD;
             long as their hearing is adequate to hear the sounds on the study devices. If&#xD;
             necessary, potential study participants will receive a brief test trial with the&#xD;
             RESPeRATE device. If they indicate inability to hear the guiding tones, they will not&#xD;
             be enrolled in the study.&#xD;
&#xD;
        Cortisol Exclusion&#xD;
&#xD;
        - Participants with endocrine disorders (e.g., diabetes and thyroid disorders) or on&#xD;
        steroid-based medications are excluded from the cortisol portion of the study (with the&#xD;
        exception of topical hydrocortisone that is permitted).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne C Danhauer, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Glenn Lesser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beebe Health Campus</name>
      <address>
        <city>Rehoboth Beach</city>
        <state>Delaware</state>
        <zip>19971</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas-Wichita Medical Arts Tower</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Southdale Hospital</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John's Hospital - Healtheast</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott-Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margaret R Pardee Memorial Hospital</name>
      <address>
        <city>Hendersonville</city>
        <state>North Carolina</state>
        <zip>28791</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prisma Health Greenville Memorial Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pal GK, Velkumary S, Madanmohan. Effect of short-term practice of breathing exercises on autonomic functions in normal human volunteers. Indian J Med Res. 2004 Aug;120(2):115-21.</citation>
    <PMID>15347862</PMID>
  </reference>
  <reference>
    <citation>National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395-409. doi: 10.1056/NEJMoa1102873. Epub 2011 Jun 29.</citation>
    <PMID>21714641</PMID>
  </reference>
  <reference>
    <citation>Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, Sabichi AL, Smith-Bindman R, Wood DE, Qaseem A, Detterbeck FC. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012 Jun 13;307(22):2418-29. doi: 10.1001/jama.2012.5521. Review. Erratum in: JAMA. 2012 Oct 3;308(13):1324. JAMA. 2013 Jun 5;309(21):2212.</citation>
    <PMID>22610500</PMID>
  </reference>
  <reference>
    <citation>Wender R, Fontham ET, Barrera E Jr, Colditz GA, Church TR, Ettinger DS, Etzioni R, Flowers CR, Gazelle GS, Kelsey DK, LaMonte SJ, Michaelson JS, Oeffinger KC, Shih YC, Sullivan DC, Travis W, Walter L, Wolf AM, Brawley OW, Smith RA. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013 Mar-Apr;63(2):107-17. doi: 10.3322/caac.21172. Epub 2013 Jan 11. Review.</citation>
    <PMID>23315954</PMID>
  </reference>
  <reference>
    <citation>Doria-Rose VP, White MC, Klabunde CN, Nadel MR, Richards TB, McNeel TS, Rodriguez JL, Marcus PM. Use of lung cancer screening tests in the United States: results from the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1049-59. doi: 10.1158/1055-9965.EPI-12-0343. Epub 2012 May 9.</citation>
    <PMID>22573798</PMID>
  </reference>
  <reference>
    <citation>Alfano CM, Rowland JH. Recovery issues in cancer survivorship: a new challenge for supportive care. Cancer J. 2006 Sep-Oct;12(5):432-43. Review.</citation>
    <PMID>17034679</PMID>
  </reference>
  <reference>
    <citation>Hodgkinson K, Butow P, Fuchs A, Hunt GE, Stenlake A, Hobbs KM, Brand A, Wain G. Long-term survival from gynecologic cancer: psychosocial outcomes, supportive care needs and positive outcomes. Gynecol Oncol. 2007 Feb;104(2):381-9. Epub 2006 Oct 5.</citation>
    <PMID>17027072</PMID>
  </reference>
  <reference>
    <citation>Jacobsen PB DKSZetal. Management of anxiety and depression in adult cancer patients: Toward an evidence-based approach. In: Chang AE GPHDea, editor. Oncology: An Evidence-Based Approach. Philadelphia, PA: Springer; 2006. p. 1552-79.</citation>
  </reference>
  <reference>
    <citation>Jefford M, Karahalios E, Pollard A, Baravelli C, Carey M, Franklin J, Aranda S, Schofield P. Survivorship issues following treatment completion--results from focus groups with Australian cancer survivors and health professionals. J Cancer Surviv. 2008 Mar;2(1):20-32. doi: 10.1007/s11764-008-0043-4. Epub 2008 Jan 25.</citation>
    <PMID>18648984</PMID>
  </reference>
  <reference>
    <citation>Stanton AL, Bower JE, Low CA. Posttraumatic Growth After Cancer. In 2006. p. 138-75.</citation>
  </reference>
  <reference>
    <citation>Brintzenhofe-Szoc KM, Levin TT, Li Y, Kissane DW, Zabora JR. Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics. 2009 Jul-Aug;50(4):383-91. doi: 10.1176/appi.psy.50.4.383.</citation>
    <PMID>19687179</PMID>
  </reference>
  <reference>
    <citation>Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology. 2001 Jan-Feb;10(1):19-28.</citation>
    <PMID>11180574</PMID>
  </reference>
  <reference>
    <citation>Li J, Girgis A. Supportive care needs: are patients with lung cancer a neglected population? Psychooncology. 2006 Jun;15(6):509-16.</citation>
    <PMID>16292789</PMID>
  </reference>
  <reference>
    <citation>Baker F, Denniston M, Smith T, West MM. Adult cancer survivors: how are they faring? Cancer. 2005 Dec 1;104(11 Suppl):2565-76.</citation>
    <PMID>16258929</PMID>
  </reference>
  <reference>
    <citation>Uchitomi Y, Mikami I, Nagai K, Nishiwaki Y, Akechi T, Okamura H. Depression and psychological distress in patients during the year after curative resection of non-small-cell lung cancer. J Clin Oncol. 2003 Jan 1;21(1):69-77.</citation>
    <PMID>12506173</PMID>
  </reference>
  <reference>
    <citation>Ostroff JS, Krebs P, Coups EJ, Burkhalter JE, Feinstein MB, Steingart RM, Logue AE, Park BJ. Health-related quality of life among early-stage, non-small cell, lung cancer survivors. Lung Cancer. 2011 Jan;71(1):103-8. doi: 10.1016/j.lungcan.2010.04.011. Epub 2010 May 11.</citation>
    <PMID>20462654</PMID>
  </reference>
  <reference>
    <citation>Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010 Aug 19;363(8):733-42. doi: 10.1056/NEJMoa1000678.</citation>
    <PMID>20818875</PMID>
  </reference>
  <reference>
    <citation>Hung R, Krebs P, Coups EJ, Feinstein MB, Park BJ, Burkhalter J, Ostroff JS. Fatigue and functional impairment in early-stage non-small cell lung cancer survivors. J Pain Symptom Manage. 2011 Feb;41(2):426-35. doi: 10.1016/j.jpainsymman.2010.05.017. Epub 2011 Jan 8.</citation>
    <PMID>21216563</PMID>
  </reference>
  <reference>
    <citation>Linden W, Vodermaier A, Mackenzie R, Greig D. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord. 2012 Dec 10;141(2-3):343-51. doi: 10.1016/j.jad.2012.03.025. Epub 2012 Jun 21.</citation>
    <PMID>22727334</PMID>
  </reference>
  <reference>
    <citation>Smith EL, Hann DM, Ahles TA, Furstenberg CT, Mitchell TA, Meyer L, Maurer LH, Rigas J, Hammond S. Dyspnea, anxiety, body consciousness, and quality of life in patients with lung cancer. J Pain Symptom Manage. 2001 Apr;21(4):323-9.</citation>
    <PMID>11312047</PMID>
  </reference>
  <reference>
    <citation>Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y. Prevalence and screening of dyspnea interfering with daily life activities in ambulatory patients with advanced lung cancer. J Pain Symptom Manage. 2002 Jun;23(6):484-9.</citation>
    <PMID>12067772</PMID>
  </reference>
  <reference>
    <citation>Dudgeon DJ, Lertzman M, Askew GR. Physiological changes and clinical correlations of dyspnea in cancer outpatients. J Pain Symptom Manage. 2001 May;21(5):373-9.</citation>
    <PMID>11369157</PMID>
  </reference>
  <reference>
    <citation>Henoch I, Bergman B, Danielson E. Dyspnea experience and management strategies in patients with lung cancer. Psychooncology. 2008 Jul;17(7):709-15.</citation>
    <PMID>18074408</PMID>
  </reference>
  <reference>
    <citation>Ryan LS. Psychosocial issues and lung cancer: a behavioral approach. Semin Oncol Nurs. 1996 Nov;12(4):318-23. Review.</citation>
    <PMID>8936648</PMID>
  </reference>
  <reference>
    <citation>Hopwood P, Stephens RJ. Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party. Br J Cancer. 1995 Mar;71(3):633-6.</citation>
    <PMID>7533520</PMID>
  </reference>
  <reference>
    <citation>Muers MF, Round CE. Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group. Thorax. 1993 Apr;48(4):339-43.</citation>
    <PMID>7685550</PMID>
  </reference>
  <reference>
    <citation>Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. Chest. 1986 Feb;89(2):234-6.</citation>
    <PMID>3943383</PMID>
  </reference>
  <reference>
    <citation>Sarna L, Evangelista L, Tashkin D, Padilla G, Holmes C, Brecht ML, Grannis F. Impact of respiratory symptoms and pulmonary function on quality of life of long-term survivors of non-small cell lung cancer. Chest. 2004 Feb;125(2):439-45.</citation>
    <PMID>14769722</PMID>
  </reference>
  <reference>
    <citation>Feinstein MB, Krebs P, Coups EJ, Park BJ, Steingart RM, Burkhalter J, Logue A, Ostroff JS. Current dyspnea among long-term survivors of early-stage non-small cell lung cancer. J Thorac Oncol. 2010 Aug;5(8):1221-6. doi: 10.1097/JTO.0b013e3181df61c8.</citation>
    <PMID>20592631</PMID>
  </reference>
  <reference>
    <citation>Tishelman C, Degner LF, Rudman A, Bertilsson K, Bond R, Broberger E, Doukkali E, Levealahti H. Symptoms in patients with lung carcinoma: distinguishing distress from intensity. Cancer. 2005 Nov 1;104(9):2013-21.</citation>
    <PMID>16178002</PMID>
  </reference>
  <reference>
    <citation>Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y. Factors correlated with dyspnea in advanced lung cancer patients: organic causes and what else? J Pain Symptom Manage. 2002 Jun;23(6):490-500.</citation>
    <PMID>12067773</PMID>
  </reference>
  <reference>
    <citation>O'Driscoll M, Corner J, Bailey C. The experience of breathlessness in lung cancer. Eur J Cancer Care (Engl). 1999 Mar;8(1):37-43.</citation>
    <PMID>10362952</PMID>
  </reference>
  <reference>
    <citation>Gupta D, Lis CG, Grutsch JF. The relationship between dyspnea and patient satisfaction with quality of life in advanced cancer. Support Care Cancer. 2007 May;15(5):533-8. Epub 2006 Nov 21.</citation>
    <PMID>17120067</PMID>
  </reference>
  <reference>
    <citation>Wilhelm FH, Gevirtz R, Roth WT. Respiratory dysregulation in anxiety, functional cardiac, and pain disorders. Assessment, phenomenology, and treatment. Behav Modif. 2001 Sep;25(4):513-45. Review.</citation>
    <PMID>11530714</PMID>
  </reference>
  <reference>
    <citation>Clark ME, Hirschman R. Effects of paced respiration on anxiety reduction in a clinical population. Biofeedback Self Regul. 1990 Sep;15(3):273-84.</citation>
    <PMID>2223892</PMID>
  </reference>
  <reference>
    <citation>Eisen AR, Rapee RM, Barlow DH. The effects of breathing rate and pCO2 levels on relaxation and anxiety in a non-clinical population. Journal of Anxiety Disorders 1990;4(3):183-90</citation>
  </reference>
  <reference>
    <citation>Hazlett-Stevens H, Craske MG. BREATHING RETRAINING AND DIAPHRAGMATIC BREATHING. In General principles and empirically supported techniques of cognitive behavior therapy. 2009.</citation>
  </reference>
  <reference>
    <citation>Zhao I, Yates P. Non-pharmacological interventions for breathlessness management in patients with lung cancer: a systematic review. Palliat Med. 2008 Sep;22(6):693-701. doi: 10.1177/0269216308095024. Review.</citation>
    <PMID>18715967</PMID>
  </reference>
  <reference>
    <citation>Bredin M, Corner J, Krishnasamy M, Plant H, Bailey C, A'Hern R. Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer. BMJ. 1999 Apr 3;318(7188):901-4.</citation>
    <PMID>10102851</PMID>
  </reference>
  <reference>
    <citation>Corner J, Plant H, A'Hern R, Bailey C. Non-pharmacological intervention for breathlessness in lung cancer. Palliat Med. 1996 Oct;10(4):299-305.</citation>
    <PMID>8931065</PMID>
  </reference>
  <reference>
    <citation>Schein MH, Gavish B, Herz M, Rosner-Kahana D, Naveh P, Knishkowy B, Zlotnikov E, Ben-Zvi N, Melmed RN. Treating hypertension with a device that slows and regularises breathing: a randomised, double-blind controlled study. J Hum Hypertens. 2001 Apr;15(4):271-8.</citation>
    <PMID>11319676</PMID>
  </reference>
  <reference>
    <citation>Elliot WJ, Izzo JL Jr, White WB, Rosing DR, Snyder CS, Alter A, Gavish B, Black HR. Graded blood pressure reduction in hypertensive outpatients associated with use of a device to assist with slow breathing. J Clin Hypertens (Greenwich). 2004 Oct;6(10):553-9; quiz 560-1.</citation>
    <PMID>15470284</PMID>
  </reference>
  <reference>
    <citation>Logtenberg SJ, Kleefstra N, Houweling ST, Groenier KH, Bilo HJ. Effect of device-guided breathing exercises on blood pressure in hypertensive patients with type 2 diabetes mellitus: a randomized controlled trial. J Hypertens. 2007 Jan;25(1):241-6.</citation>
    <PMID>17143197</PMID>
  </reference>
  <reference>
    <citation>Meles E, Giannattasio C, Failla M, Gentile G, Capra A, Mancia G. Nonpharmacologic treatment of hypertension by respiratory exercise in the home setting. Am J Hypertens. 2004 Apr;17(4):370-4.</citation>
    <PMID>15062893</PMID>
  </reference>
  <reference>
    <citation>Coups EJ, Ostroff JS. A population-based estimate of the prevalence of behavioral risk factors among adult cancer survivors and noncancer controls. Prev Med. 2005 Jun;40(6):702-11.</citation>
    <PMID>15850868</PMID>
  </reference>
  <reference>
    <citation>Grossman E, Grossman A, Schein MH, Zimlichman R, Gavish B. Breathing-control lowers blood pressure. J Hum Hypertens. 2001 Apr;15(4):263-9.</citation>
    <PMID>11319675</PMID>
  </reference>
  <reference>
    <citation>Schein MH, Gavish B, Baevsky T, Kaufman M, Levine S, Nessing A, Alter A. Treating hypertension in type II diabetic patients with device-guided breathing: a randomized controlled trial. J Hum Hypertens. 2009 May;23(5):325-31. doi: 10.1038/jhh.2008.135. Epub 2008 Nov 13.</citation>
    <PMID>19005477</PMID>
  </reference>
  <reference>
    <citation>Ekman I, Kjellström B, Falk K, Norman J, Swedberg K. Impact of device-guided slow breathing on symptoms of chronic heart failure: a randomized, controlled feasibility study. Eur J Heart Fail. 2011 Sep;13(9):1000-5. doi: 10.1093/eurjhf/hfr090. Epub 2011 Jul 28.</citation>
    <PMID>21803755</PMID>
  </reference>
  <reference>
    <citation>Parati G, Malfatto G, Boarin S, Branzi G, Caldara G, Giglio A, Bilo G, Ongaro G, Alter A, Gavish B, Mancia G. Device-guided paced breathing in the home setting: effects on exercise capacity, pulmonary and ventricular function in patients with chronic heart failure: a pilot study. Circ Heart Fail. 2008 Sep;1(3):178-83. doi: 10.1161/CIRCHEARTFAILURE.108.772640.</citation>
    <PMID>19808287</PMID>
  </reference>
  <reference>
    <citation>Reiner R. Integrating a portable biofeedback device into clinical practice for patients with anxiety disorders: results of a pilot study. Appl Psychophysiol Biofeedback. 2008 Mar;33(1):55-61. doi: 10.1007/s10484-007-9046-6. Epub 2008 Feb 20.</citation>
    <PMID>18286369</PMID>
  </reference>
  <reference>
    <citation>Jacobsen PB, Jim HS. Psychosocial interventions for anxiety and depression in adult cancer patients: achievements and challenges. CA Cancer J Clin. 2008 Jul-Aug;58(4):214-30. doi: 10.3322/CA.2008.0003. Epub 2008 Jun 16. Review.</citation>
    <PMID>18558664</PMID>
  </reference>
  <reference>
    <citation>Mehta KM, Yaffe K, Brenes GA, Newman AB, Shorr RI, Simonsick EM, Ayonayon HN, Rubin SM, Covinsky KE. Anxiety symptoms and decline in physical function over 5 years in the health, aging and body composition study. J Am Geriatr Soc. 2007 Feb;55(2):265-70.</citation>
    <PMID>17302665</PMID>
  </reference>
  <reference>
    <citation>Schneider S, Moyer A, Knapp-Oliver S, Sohl S, Cannella D, Targhetta V. Pre-intervention distress moderates the efficacy of psychosocial treatment for cancer patients: a meta-analysis. J Behav Med. 2010 Feb;33(1):1-14. doi: 10.1007/s10865-009-9227-2. Epub 2009 Sep 27.</citation>
    <PMID>19784868</PMID>
  </reference>
  <reference>
    <citation>Weaver KE, Forsythe LP, Reeve BB, Alfano CM, Rodriguez JL, Sabatino SA, Hawkins NA, Rowland JH. Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2108-17. doi: 10.1158/1055-9965.EPI-12-0740. Epub 2012 Oct 30.</citation>
    <PMID>23112268</PMID>
  </reference>
  <reference>
    <citation>Burris JL, Andrykowski M. Disparities in mental health between rural and nonrural cancer survivors: a preliminary study. Psychooncology. 2010 Jun;19(6):637-45. doi: 10.1002/pon.1600.</citation>
    <PMID>19582800</PMID>
  </reference>
  <reference>
    <citation>Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor: Lost in Transition. 2006. National Academies Press.</citation>
  </reference>
  <reference>
    <citation>Stamm BH, Piland NF, Lambert D, Speck NC. A Rural Perspective on Health Care for the Whole Person. Professional Psychology: Research and Practice 2007;38(3):298-304</citation>
  </reference>
  <reference>
    <citation>American Psychological Association, Practice Directorate, Office of Rural Health (2002a). Caring for the rural community: 2000-2001 report. Washington, DC: APA Press; 2001.</citation>
  </reference>
  <reference>
    <citation>Jerath R, Edry JW, Barnes VA, Jerath V. Physiology of long pranayamic breathing: neural respiratory elements may provide a mechanism that explains how slow deep breathing shifts the autonomic nervous system. Med Hypotheses. 2006;67(3):566-71. Epub 2006 Apr 18.</citation>
    <PMID>16624497</PMID>
  </reference>
  <reference>
    <citation>Carrieri-Kohlman V, Gormley JM, Douglas MK, Paul SM, Stulbarg MS. Exercise training decreases dyspnea and the distress and anxiety associated with it. Monitoring alone may be as effective as coaching. Chest. 1996 Dec;110(6):1526-35.</citation>
    <PMID>8989072</PMID>
  </reference>
  <reference>
    <citation>Gallo-Silver L, Pollack B. Behavioral interventions for lung cancer-related breathlessness. Cancer Pract. 2000 Nov-Dec;8(6):268-73. Review.</citation>
    <PMID>11898143</PMID>
  </reference>
  <reference>
    <citation>Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y. Development and validation of the Cancer Dyspnoea Scale: a multidimensional, brief, self-rating scale. Br J Cancer. 2000 Feb;82(4):800-5.</citation>
    <PMID>10732749</PMID>
  </reference>
  <reference>
    <citation>Dudgeon DJ, Lertzman M. Dyspnea in the advanced cancer patient. J Pain Symptom Manage. 1998 Oct;16(4):212-9.</citation>
    <PMID>9803048</PMID>
  </reference>
  <reference>
    <citation>Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70.</citation>
    <PMID>6880820</PMID>
  </reference>
  <reference>
    <citation>Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002 Feb;52(2):69-77. Review.</citation>
    <PMID>11832252</PMID>
  </reference>
  <reference>
    <citation>Luckett T, Butow PN, King MT, Oguchi M, Heading G, Hackl NA, Rankin N, Price MA. A review and recommendations for optimal outcome measures of anxiety, depression and general distress in studies evaluating psychosocial interventions for English-speaking adults with heterogeneous cancer diagnoses. Support Care Cancer. 2010 Oct;18(10):1241-62. doi: 10.1007/s00520-010-0932-8. Epub 2010 Jul 2. Review.</citation>
    <PMID>20596731</PMID>
  </reference>
  <reference>
    <citation>Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med. 1999 Jan;159(1):321-40. Review.</citation>
    <PMID>9872857</PMID>
  </reference>
  <reference>
    <citation>Polański J, Chabowski M, Chudiak A, Uchmanowicz B, Janczak D, Rosińczuk J, Mazur G. Intensity of Anxiety and Depression in Patients with Lung Cancer in Relation to Quality of Life. Adv Exp Med Biol. 2018;1023:29-36. doi: 10.1007/5584_2017_50.</citation>
    <PMID>28573442</PMID>
  </reference>
  <reference>
    <citation>Krebber AM, Jansen F, Witte BI, Cuijpers P, de Bree R, Becker-Commissaris A, Smit EF, van Straten A, Eeckhout AM, Beekman AT, Leemans CR, Verdonck-de Leeuw IM. Stepped care targeting psychological distress in head and neck cancer and lung cancer patients: a randomized, controlled trial. Ann Oncol. 2016 Sep;27(9):1754-60. doi: 10.1093/annonc/mdw230. Epub 2016 Jun 10.</citation>
    <PMID>27287209</PMID>
  </reference>
  <reference>
    <citation>Quist M, Langer SW, Rørth M, Christensen KB, Adamsen L. &quot;EXHALE&quot;: exercise as a strategy for rehabilitation in advanced stage lung cancer patients: a randomized clinical trial comparing the effects of 12 weeks supervised exercise intervention versus usual care for advanced stage lung cancer patients. BMC Cancer. 2013 Oct 14;13:477. doi: 10.1186/1471-2407-13-477.</citation>
    <PMID>24124893</PMID>
  </reference>
  <reference>
    <citation>Aitken RC. Measurement of feelings using visual analogue scales. Proc R Soc Med. 1969 Oct;62(10):989-93. Review.</citation>
    <PMID>4899510</PMID>
  </reference>
  <reference>
    <citation>Gift AG. Validation of a vertical visual analogue scale as a measure of clinical dyspnea. Rehabil Nurs. 1989 Nov-Dec;14(6):323-5.</citation>
    <PMID>2813949</PMID>
  </reference>
  <reference>
    <citation>Mancini I, Body JJ. Assessment of dyspnea in advanced cancer patients. Support Care Cancer. 1999 Jul;7(4):229-32. Review.</citation>
    <PMID>10423048</PMID>
  </reference>
  <reference>
    <citation>Kalauokalani D, Cherkin DC, Sherman KJ, Koepsell TD, Deyo RA. Lessons from a trial of acupuncture and massage for low back pain: patient expectations and treatment effects. Spine (Phila Pa 1976). 2001 Jul 1;26(13):1418-24.</citation>
    <PMID>11458142</PMID>
  </reference>
  <reference>
    <citation>Linde K, Witt CM, Streng A, Weidenhammer W, Wagenpfeil S, Brinkhaus B, Willich SN, Melchart D. The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain. Pain. 2007 Apr;128(3):264-271. doi: 10.1016/j.pain.2006.12.006. Epub 2007 Jan 25.</citation>
    <PMID>17257756</PMID>
  </reference>
  <reference>
    <citation>Cancer of the Lung and Bronchus - SEER Stat Fact Sheets [Internet]. [cited 2012 Jul 17]. Available from: http://seer.cancer.gov/statfacts/html/lungb.html</citation>
  </reference>
  <reference>
    <citation>Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep. 1985 Dec;69(12):1375-81.</citation>
    <PMID>4075313</PMID>
  </reference>
  <reference>
    <citation>Wilson EB. Probable inference, the law of succession, and statistical inference. JASA1927;22: 209-212.</citation>
  </reference>
  <reference>
    <citation>Garcia SF, George J, Rosenbloom SK, Cella D. Adapting chronic illness health related quality of life item banks for cancer populations. In Poster presented at the International Society for Quality of LifeResearch on Patient-Reported Outcomes in Clinical Practice, Budapest, Hungary. In 2007.</citation>
  </reference>
  <reference>
    <citation>Molassiotis A, Ellis J, Wagland R, Williams ML, Bailey CD, Booton R, Blackhall F, Yorke J, Smith JA. The Manchester cough in lung cancer scale: the development and preliminary validation of a new assessment tool. J Pain Symptom Manage. 2013 Feb;45(2):179-90. doi: 10.1016/j.jpainsymman.2012.01.015. Epub 2012 Aug 25.</citation>
    <PMID>22926094</PMID>
  </reference>
  <reference>
    <citation>Uddin M, Aiello AE, Wildman DE, Koenen KC, Pawelec G, de Los Santos R, Goldmann E, Galea S. Epigenetic and immune function profiles associated with posttraumatic stress disorder. Proc Natl Acad Sci U S A. 2010 May 18;107(20):9470-5. doi: 10.1073/pnas.0910794107. Epub 2010 May 3.</citation>
    <PMID>20439746</PMID>
  </reference>
  <reference>
    <citation>Uddin M, Koenen KC, Aiello AE, Wildman DE, de los Santos R, Galea S. Epigenetic and inflammatory marker profiles associated with depression in a community-based epidemiologic sample. Psychol Med. 2011 May;41(5):997-1007. doi: 10.1017/S0033291710001674. Epub 2010 Sep 14.</citation>
    <PMID>20836906</PMID>
  </reference>
  <reference>
    <citation>El-Sayed AM, Haloossim MR, Galea S, Koenen KC. Epigenetic modifications associated with suicide and common mood and anxiety disorders: a systematic review of the literature. Biol Mood Anxiety Disord. 2012 Jun 14;2:10. doi: 10.1186/2045-5380-2-10.</citation>
    <PMID>22738307</PMID>
  </reference>
  <reference>
    <citation>Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, Dymov S, Szyf M, Meaney MJ. Epigenetic programming by maternal behavior. Nat Neurosci. 2004 Aug;7(8):847-54. Epub 2004 Jun 27.</citation>
    <PMID>15220929</PMID>
  </reference>
  <reference>
    <citation>Aldwin, C M, The physiology of stress, in Stress, Coping, and Development Guilford Press: New York, NY. 2007; 39-54.</citation>
  </reference>
  <reference>
    <citation>Murphy SE, Braithwaite EC, Hubbard I, Williams KV, Tindall E, Holmes EA, Ramchandani PG. Salivary cortisol response to infant distress in pregnant women with depressive symptoms. Arch Womens Ment Health. 2015 Apr;18(2):247-253. doi: 10.1007/s00737-014-0473-0. Epub 2014 Oct 29. Erratum in: Arch Womens Ment Health. 2019 Apr;22(2):313.</citation>
    <PMID>25352317</PMID>
  </reference>
  <reference>
    <citation>Schrepf A, Clevenger L, Christensen D, DeGeest K, Bender D, Ahmed A, Goodheart MJ, Dahmoush L, Penedo F, Lucci JA 3rd, Ganjei-Azar P, Mendez L, Markon K, Lubaroff DM, Thaker PH, Slavich GM, Sood AK, Lutgendorf SK. Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability. Brain Behav Immun. 2013 Mar;30 Suppl:S126-34. doi: 10.1016/j.bbi.2012.07.022. Epub 2012 Aug 5.</citation>
    <PMID>22884960</PMID>
  </reference>
  <reference>
    <citation>Stoppelbein L, Greening L. A longitudinal study of the role of cortisol in posttraumatic stress disorder symptom clusters. Anxiety Stress Coping. 2015;28(1):17-30. doi: 10.1080/10615806.2014.923844. Epub 2014 Jun 17.</citation>
    <PMID>24824647</PMID>
  </reference>
  <reference>
    <citation>Vadiraja HS, Raghavendra RM, Nagarathna R, Nagendra HR, Rekha M, Vanitha N, Gopinath KS, Srinath BS, Vishweshwara MS, Madhavi YS, Ajaikumar BS, Ramesh BS, Nalini R, Kumar V. Effects of a yoga program on cortisol rhythm and mood states in early breast cancer patients undergoing adjuvant radiotherapy: a randomized controlled trial. Integr Cancer Ther. 2009 Mar;8(1):37-46. doi: 10.1177/1534735409331456. Epub 2009 Feb 3. Erratum in: Integr Cancer Ther. 2009 Jun;8(2):195.</citation>
    <PMID>19190034</PMID>
  </reference>
  <reference>
    <citation>Cruess DG, Antoni MH, McGregor BA, Kilbourn KM, Boyers AE, Alferi SM, Carver CS, Kumar M. Cognitive-behavioral stress management reduces serum cortisol by enhancing benefit finding among women being treated for early stage breast cancer. Psychosom Med. 2000 May-Jun;62(3):304-8.</citation>
    <PMID>10845343</PMID>
  </reference>
  <reference>
    <citation>Nickel C, Tanca S, Kolowos S, Pedrosa-Gil F, Bachler E, Loew TH, Gross M, Rother WK, Nickel MK. Men with chronic occupational stress benefit from behavioural/psycho-educational group training: a randomized, prospective, controlled trial. Psychol Med. 2007 Aug;37(8):1141-9. Epub 2006 Dec 6.</citation>
    <PMID>17147835</PMID>
  </reference>
  <reference>
    <citation>Boyes A, D'Este C, Carey M, Lecathelinais C, Girgis A. How does the Distress Thermometer compare to the Hospital Anxiety and Depression Scale for detecting possible cases of psychological morbidity among cancer survivors? Support Care Cancer. 2013 Jan;21(1):119-27. doi: 10.1007/s00520-012-1499-3. Epub 2012 May 24.</citation>
    <PMID>22618735</PMID>
  </reference>
  <reference>
    <citation>Donovan KA, Grassi L, McGinty HL, Jacobsen PB. Validation of the distress thermometer worldwide: state of the science. Psychooncology. 2014 Mar;23(3):241-50. doi: 10.1002/pon.3430. Epub 2013 Nov 11. Review.</citation>
    <PMID>25160838</PMID>
  </reference>
  <reference>
    <citation>Ma X, Zhang J, Zhong W, Shu C, Wang F, Wen J, Zhou M, Sang Y, Jiang Y, Liu L. The diagnostic role of a short screening tool--the distress thermometer: a meta-analysis. Support Care Cancer. 2014 Jul;22(7):1741-55. doi: 10.1007/s00520-014-2143-1. Epub 2014 Feb 8.</citation>
    <PMID>24510195</PMID>
  </reference>
  <reference>
    <citation>Custers JA, van den Berg SW, van Laarhoven HW, Bleiker EM, Gielissen MF, Prins JB. The Cancer Worry Scale: detecting fear of recurrence in breast cancer survivors. Cancer Nurs. 2014 Jan-Feb;37(1):E44-50. doi: 10.1097/NCC.0b013e3182813a17.</citation>
    <PMID>23448956</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 27, 2014</study_first_submitted>
  <study_first_submitted_qc>February 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2014</study_first_posted>
  <results_first_submitted>January 8, 2021</results_first_submitted>
  <results_first_submitted_qc>January 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2021</results_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anxiety</keyword>
  <keyword>Dyspnea</keyword>
  <keyword>respiratory functioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT02063828/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT02063828/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Implementation was facilitated through the Wake Forest National Cancer Institute Community Oncology Research Program (NCORP), developed to increase community participation in cancer trials. Forty-six participants were accrued between July 30 2015 and June 11 2019 (0.99 participants/month).</recruitment_details>
      <pre_assignment_details>In this feasibility study, participants were stratified by baseline self-reported dyspnea score and randomized to a 12-week high-dose or low-dose device-guided breathing intervention versus a usual breathing control group with equal probability, using variable length permuted block randomization. All participants enrolled were randomized and included in analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A - Device Guided Breathing Low Dose. 15 Minutes Once a Day, 5 Days a Week for 12 Weeks.</title>
          <description>Group A - Device Guided Breathing Low Dose&#xD;
Group A - Device guided breathing low dose: Group A: 15 minutes once a day, 5 days a week for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Group B - Device Guided Breathing High Dose. 15 Minutes Twice a Day, 5 Days a Week for 12 Weeks.</title>
          <description>Group B - Device guided breathing high dose&#xD;
Group B - Device guided breathing high dose: Group B - 15 minutes twice a day, 5 days a week for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Group C - Usual Breathing Control Group. 15 Minutes Per Day, 5 Days a Week for 12 Weeks.</title>
          <description>Group C - Usual Breathing Control Group&#xD;
Group C - Usual Breathing Control Group: Group C - 15 minutes per day, 5 days a week for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 6</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>Group A - Device Guided Breathing Low Dose&#xD;
Group A - Device guided breathing low dose: Group A: 15 minutes once a day, 5 days a week for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>Group B - Device guided breathing high dose&#xD;
Group B - Device guided breathing high dose: Group B - 15 minutes twice a day, 5 days a week for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Group C</title>
          <description>Group C - Usual Breathing Control Group&#xD;
Group C - Usual Breathing Control Group: Group C - 15 minutes per day, 5 days a week for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="45" upper_limit="76"/>
                    <measurement group_id="B2" value="64" lower_limit="41" upper_limit="77"/>
                    <measurement group_id="B3" value="66" lower_limit="43" upper_limit="74"/>
                    <measurement group_id="B4" value="65" lower_limit="41" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <title>&gt;=50 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&lt;50</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer Dyspnea Scale</title>
          <description>12-item self-report measure of multidimensional (sense of effort, sense of anxiety, discomfort) nature of dyspnea. Reliable and valid in lung cancer patients. Scores range from 0-44 and clinical dyspnea is considered total scores greater than or equal to 8. Higher scores reflect more dyspnea. Selected as an optimal measure of dyspnea since it assesses multiple symptom components and is validated for use in cancer survivors.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;8</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=8</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Single</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Married</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Separated/Divorced/Widowed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Income</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Under $20,000</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>$20,000 - $49,999</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>$50,000 or more</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>High School or Less</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>College graduate or some college</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Post College Graduate Education</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage of Disease</title>
          <description>Clinical staging of the disease based on the American Joint Committee on Cancer (AJCC) system. Ranges from 0 to IV with higher numbers reflecting more severe disease. In non-small cell lung cancer stage 0 is where the tumor is found only in the top layers of cells lining the air passages, but it has not invaded deeper into other lung tissues to stage IV where it has spread to the other lung or other areas of the body.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <description>Standardizes how the disease impacts a patient's daily living abilities. Scale ranges from 0 to 5. Higher scores are worse. 0-Fully active, able to carry on all pre-disease performance without restriction; 1-Restricted in physically strenuous activity but ambulatory and able to carry out light/sedentary work; 2-Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about &gt;50% waking hours; 3-Capable of only limited selfcare; confined to bed or chair &gt;50% waking hours; 4-Completely disabled; cannot carry on any selfcare; totally confined to bed/chair; 5-Dead</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Smoker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Retention - Number of Participants Who Complete the Final Assessment</title>
        <description>Retention will be calculated as the number of participants who complete the final assessment divided by number randomized.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Group A - Device Guided Breathing Low Dose&#xD;
Group A - Device guided breathing low dose: Group A: 15 minutes once a day, 5 days a week for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Group B - Device guided breathing high dose&#xD;
Group B - Device guided breathing high dose: Group B - 15 minutes twice a day, 5 days a week for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Group C - Usual Breathing Control Group&#xD;
Group C - Usual Breathing Control Group: Group C - 15 minutes per day, 5 days a week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Retention - Number of Participants Who Complete the Final Assessment</title>
          <description>Retention will be calculated as the number of participants who complete the final assessment divided by number randomized.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adherence- Amount of Time the Device is Used</title>
        <description>Adherence will be calculated as the actual amount of time the device is used divided by the prescribed time. Successful adherence will be defined as use of the device ≥80% of the time assigned.</description>
        <time_frame>12 weeks</time_frame>
        <population>Adherence data used visits up to withdrawal or study completion. Includes 5 participants missing all breathing visits. Excludes 2 participants that withdrew at baseline and have no available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Group A - Device Guided Breathing Low Dose&#xD;
Group A - Device guided breathing low dose: Group A: 15 minutes once a day, 5 days a week for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Group B - Device guided breathing high dose&#xD;
Group B - Device guided breathing high dose: Group B - 15 minutes twice a day, 5 days a week for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Group C - Usual Breathing Control Group&#xD;
Group C - Usual Breathing Control Group: Group C - 15 minutes per day, 5 days a week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence- Amount of Time the Device is Used</title>
          <description>Adherence will be calculated as the actual amount of time the device is used divided by the prescribed time. Successful adherence will be defined as use of the device ≥80% of the time assigned.</description>
          <population>Adherence data used visits up to withdrawal or study completion. Includes 5 participants missing all breathing visits. Excludes 2 participants that withdrew at baseline and have no available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 1-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 7-12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accrual Rate- Number of Patients Accrued to the Study</title>
        <description>The accrual rate will be calculated as the number of patients accrued to the study divided by the number of months of accrual.</description>
        <time_frame>Time from study opening to study close ~46.42 months</time_frame>
        <population>Participants were accrued between July 30 2015 and June 11 2019 for a total of 46.42 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Group A - Device Guided Breathing Low Dose&#xD;
Group A - Device guided breathing low dose: Group A: 15 minutes once a day, 5 days a week for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Group B - Device guided breathing high dose&#xD;
Group B - Device guided breathing high dose: Group B - 15 minutes twice a day, 5 days a week for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Group C - Usual Breathing Control Group&#xD;
Group C - Usual Breathing Control Group: Group C - 15 minutes per day, 5 days a week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Accrual Rate- Number of Patients Accrued to the Study</title>
          <description>The accrual rate will be calculated as the number of patients accrued to the study divided by the number of months of accrual.</description>
          <population>Participants were accrued between July 30 2015 and June 11 2019 for a total of 46.42 months.</population>
          <units>participants per month</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30"/>
                    <measurement group_id="O2" value="0.30"/>
                    <measurement group_id="O3" value="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for Anxiety as Measured by Hospital Anxiety and Depression Scale (HADS)</title>
        <description>To obtain preliminary data on the variability and efficacy of two doses of a device-guided breathing intervention versus a usual breathing control group for reducing anxiety. This is a 14-item self-report measure of cognitive and behavioral symptoms of anxiety and depression; clinically significant symptoms are indicated by a score of greater than or equal to 8 with a range from 0 to 42. Higher scores indicate more anxiety.</description>
        <time_frame>12 weeks</time_frame>
        <population>All data was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Group A - Device Guided Breathing Low Dose&#xD;
Group A - Device guided breathing low dose: Group A: 15 minutes once a day, 5 days a week for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Group B - Device guided breathing high dose&#xD;
Group B - Device guided breathing high dose: Group B - 15 minutes twice a day, 5 days a week for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Group C - Usual Breathing Control Group&#xD;
Group C - Usual Breathing Control Group: Group C - 15 minutes per day, 5 days a week for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Anxiety as Measured by Hospital Anxiety and Depression Scale (HADS)</title>
          <description>To obtain preliminary data on the variability and efficacy of two doses of a device-guided breathing intervention versus a usual breathing control group for reducing anxiety. This is a 14-item self-report measure of cognitive and behavioral symptoms of anxiety and depression; clinically significant symptoms are indicated by a score of greater than or equal to 8 with a range from 0 to 42. Higher scores indicate more anxiety.</description>
          <population>All data was utilized.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to 6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" lower_limit="-2.90" upper_limit="0.45"/>
                    <measurement group_id="O2" value="-2.38" lower_limit="-4.34" upper_limit="-0.43"/>
                    <measurement group_id="O3" value="-1.75" lower_limit="-3.21" upper_limit="-0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.27" lower_limit="-3.55" upper_limit="-0.99"/>
                    <measurement group_id="O2" value="-2.10" lower_limit="-3.74" upper_limit="-0.45"/>
                    <measurement group_id="O3" value="-1.89" lower_limit="-3.01" upper_limit="-0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Salivary Cortisol Levels</title>
        <description>Cortisol levels will be assessed upon awakening, 30 minutes post-awakening, and at bedtime for three consecutive days at baseline and three consecutive days.</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>DNA Methylation Levels</title>
        <description>DNA methylation levels will be measured To determine if changes in anxiety are associated with methylation</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Gene Expression Levels</title>
        <description>The DNA methylation and gene expression patterns between the different groups.</description>
        <time_frame>12 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event/Serious Adverse Event reporting begins after the informed consent is signed and is followed for 30 days post study completion, an average of 16 weeks</time_frame>
      <desc>Only report unexpected serious adverse events, Grades 4 and 5, which are related to the use of the breathing device used in this study. Serious Adverse Events occurring within 30 days of study completion must be reported via FDA Form 3500 (MedWatch).</desc>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>Group A - Device Guided Breathing Low Dose&#xD;
Group A - Device guided breathing low dose: Group A: 15 minutes once a day, 5 days a week for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>Group B - Device guided breathing high dose&#xD;
Group B - Device guided breathing high dose: Group B - 15 minutes twice a day, 5 days a week for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Group C</title>
          <description>Group C - Usual Breathing Control Group&#xD;
Group C - Usual Breathing Control Group: Group C - 15 minutes per day, 5 days a week for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Trial terminated early due to slow accrual.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Emily Dressler, PhD</name_or_title>
      <organization>Wake Forest NCORP Research Base</organization>
      <phone>336 716-0891</phone>
      <email>ncorp@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

